Develops ECM-targeted therapies using ECM-specific nanobody binders to deliver potent payloads directly to tumor and metastatic extracellular matrix, maximizing precision and sparing healthy tissue. Platform supports ECM-targeted radiopharmaceuticals (lead asset), antibody–drug conjugates, immunomodulatory and fibrosis-targeted treatments.